Astonea Labs Board Approves IPO Proceeds Variation and Related Party Transactions Worth Rs. 415 Crore
Published on: Feb. 27, 2026, 7:05 p.m. | Source: scanx.trade
Astonea Labs Limited's board approved variation in IPO proceeds utilization of Rs. 6.25 crore for acquiring 20-21% stake in Damaira Pharmaceuticals Private Limited, representing 16.59% deviation from original objects. The board also granted omnibus approval for material related party transactions worth Rs. 415 crore for FY 2026-27, with major transactions planned with Astonea One Private Limited and other related entities. An Extraordinary General Meeting has been scheduled for 27th March, 2026, to seek shareholder approval for these proposals along with adoption of new Articles of Association and other corporate matters.
